多索茶碱联合黄芪治疗稳定性慢性阻塞性肺部疾病临床观察-《西部中医药》

文章信息/Info

Title:: Clinical Observation on Doxofylline Joined with HuangQi in Treating Stable Chronic Obstructive Pulmonary Disease

Author(s):: ZHU Wenjing; Respiratory Department, Hongze District People′s Hospital of Huai′an Municipality, Huai′an 223100, China

摘要:: 目的：探讨多索茶碱联合黄芪治疗稳定期慢性阻塞性肺部疾病的临床价值。方法：将慢性阻塞性肺部疾病稳定期患者80例按照随机数字表法分为观察组与对照组各40例，对照组在对症支持处理基础上使用黄芪，观察组在对照组基础上联合多索茶碱，比较2组患者干预前后生存质量、生活能力、肺功能及SGRQ评分变化情况。结果：干预后观察组生存质量及生活能力评分均优于对照组（P＜0.05），FEV1及FEV1/FVC水平高于对照组（P＜0.05），干预后2周及出院时观察组患者SGRQ评分低于对照组（P＜0.05）。结论：针对稳定期慢性阻塞性肺部疾病患者使用多索茶碱联合黄芪治疗，能有效改善患者肺功能，缓解临床症状，提高生活质量及生存能力。

Abstract:: Objective: To survey clinical value of doxofylline combined with HuangQi[Astragalus membranaceus (Fisch.) Bunge.] in treating stable chronic obstructive pulmonary disease (COPD). Methods: Eighty COPD patients were allocated to the observation group and the control group according to random number method, 40 cases each group, the control group used HuangQi on the foundation of symptomatic support treatment, and the observation group were given doxofylline, the changes of SGRQ before and after the intervention, pulmonary function after the intervention, living ability and quality of life were compared. Results: After the intervention, the observation group was superior to the control group in the scores of quality of life and living ability notably after the intervention (P＜0.05), after the intervention, FEV1 , FEV1/FVC larger than these of the control group (P＜0.05), the observation group was lower than the control group in SGRQ scores in two weeks after the intervention and when the patients were discharged(P＜0.05). Conclusion: Doxofylline combined with HuangQi in treating stable COPD could effectively improve pulmonary function of the patients, relieve clinical symptoms, raise quality of life and living ability.